01:30 PM EDT, 05/13/2024 (MT Newswires) -- Trinity Biotech ( TRIB ) said Monday it secured additional orders for its TrinScreen HIV rapid test product, boosting total orders so far this year to roughly $6 million.
The company said it has ramped up production amid increased demand, adding that it now expects 2024 sales revenue for TrinScreen HIV to be over $8 million.
Shares of the company fell more than 2% in recent trading.
Price: 1.62, Change: -0.04, Percent Change: -2.41